Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M.

Lancet Oncol. 2019 Jan 15. pii: S1470-2045(18)30784-8. doi: 10.1016/S1470-2045(18)30784-8. [Epub ahead of print]

PMID:
30658935
2.

Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.

Chaoui D, Hacini M, Fitoussi O, Karlin L, Arkam Y, Jourdan E, Orfeuvre H, Voillat L, Sanhes L, Leprêtre S, Liu KL, Barry M, Tempescul A, Dilhuydy MS, Chaib A, Slama B, Labourey JL, Benbrahim O, Dreyfus B, Mahé B, Maynadié M, Delmer A, Benkanoun C, Boissard F, Gandon S, Veerabudun K, Choquet S; on behalf of the PERLE investigators .

Leuk Lymphoma. 2019 Jan 9:1-5. doi: 10.1080/10428194.2018.1533130. [Epub ahead of print] No abstract available.

PMID:
30624147
3.

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.

Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouadallah K, Amorin S, Garidi R, Voillat L, Joly B, Celigny PS, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB; Lymphoma Study Association.

Haematologica. 2019 Jan;104(1):138-146. doi: 10.3324/haematol.2018.191429. Epub 2018 Aug 31.

4.

Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy.

Bordron A, Bagacean C, Mohr A, Tempescul A, Bendaoud B, Deshayes S, Dalbies F, Buors C, Saad H, Berthou C, Pers JO, Renaudineau Y.

Oncotarget. 2018 Aug 3;9(60):31590-31605. doi: 10.18632/oncotarget.25657. eCollection 2018 Aug 3.

5.

Preserved lenalidomide efficacy in a recurrent isolated subcutaneous mantle cell lymphoma relapse.

Bagacean C, Neaga A, Zdrenghea M, Tempescul A.

J BUON. 2018 Jan-Feb;23(1):273-274. No abstract available.

PMID:
29552797
6.

DNA demethylation marks in chronic lymphocytic leukemia: it is time to let the cat out of the bag.

Bagacean C, Zdrenghea M, Dantec CL, Tempescul A, Berthou C, Renaudineau Y.

Future Sci OA. 2017 Nov 3;4(2):FSO265. doi: 10.4155/fsoa-2017-0120. eCollection 2018 Feb. No abstract available.

7.

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).

Le Calloch R, Lacut K, Le Gall-Ianotto C, Nowak E, Abiven M, Tempescul A, Dalbies F, Eveillard JR, Ugo V, Giraudier S, Guillerm G, Lippert E, Berthou C, Ianotto JC.

Haematologica. 2018 Apr;103(4):607-613. doi: 10.3324/haematol.2017.180448. Epub 2017 Dec 15.

8.

Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion.

Bagacean C, Le Dantec C, Berthou C, Tempescul A, Saad H, Bordron A, Zdrenghea M, Cristea V, Douet-Guilbert N, Renaudineau Y.

Clin Epigenetics. 2017 Nov 28;9:122. doi: 10.1186/s13148-017-0422-7. eCollection 2017.

9.

Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia.

Bagacean C, Tempescul A, Le Dantec C, Bordron A, Mohr A, Saad H, Olivier V, Zdrenghea M, Cristea V, Cartron PF, Douet-Guilbert N, Berthou C, Renaudineau Y.

Oncotarget. 2017 Aug 9;8(39):65699-65716. doi: 10.18632/oncotarget.20081. eCollection 2017 Sep 12.

10.

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.

Ilcus C, Bagacean C, Tempescul A, Popescu C, Parvu A, Cenariu M, Bocsan C, Zdrenghea M.

Onco Targets Ther. 2017 Apr 28;10:2349-2363. doi: 10.2147/OTT.S133385. eCollection 2017. Review.

11.

Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only.

Nicol C, Henry C, Couturier MA, Delépine P, Tripogney C, Buors C, Guillerm G, Berthou C, Tempescul A, Ianotto JC.

Leuk Lymphoma. 2017 Sep;58(9):1-3. doi: 10.1080/10428194.2017.1285025. Epub 2017 Feb 7. No abstract available.

PMID:
28278727
12.

Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.

Chaoui D, Choquet S, Sanhes L, Mahé B, Hacini M, Fitoussi O, Arkam Y, Orfeuvre H, Dilhuydy MS, Barry M, Jourdan E, Dreyfus B, Tempescul A, Leprêtre S, Bardet A, Leconte P, Maynadié M, Delmer A.

Leuk Lymphoma. 2017 Jun;58(6):1366-1375. doi: 10.1080/10428194.2016.1243673. Epub 2017 Feb 9.

PMID:
28271952
13.

Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report.

Bagacean C, Tempescul A, Patiu M, Fetica B, Bumbea H, Zdrenghea M.

Onco Targets Ther. 2016 Dec 19;10:31-34. doi: 10.2147/OTT.S115892. eCollection 2017.

14.

Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus Rituximab: comparison between Deauville 5-point scale and International Harmonization Project criteria.

Lombion N, Robin P, Tempescul A, LE Roux PY, Schick U, Guillerm G, Ianotto JC, Berthou C, Salaün PY, Abgral R.

Q J Nucl Med Mol Imaging. 2016 Nov 30. [Epub ahead of print]

PMID:
27901328
15.

Isolated Cardiac Richter Syndrome: a Case Report.

Zdrenghea M, Bagacean C, Renaudineau Y, Salaun PY, Marin H, Pop D, Tempescul A.

Ann Hematol. 2017 Jan;96(1):147-149. doi: 10.1007/s00277-016-2834-4. Epub 2016 Oct 3. No abstract available.

PMID:
27696201
16.

The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.

Laribi K, Tempescul A, Ghnaya H, Denizon N, Besançon A, Anghel A, Farhi J, Truong C, Lemaire P, Poulain S, Bolle D, Ianotto JC, Baugier de Materre A.

Hematol Oncol. 2017 Dec;35(4):536-541. doi: 10.1002/hon.2334. Epub 2016 Jul 22.

PMID:
27443419
17.

Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms.

Le Gall-Ianotto C, Brenaut E, Gouillou M, Lacut K, Nowak E, Tempescul A, Berthou C, Ugo V, Carré JL, Misery L, Ianotto JC.

Br J Dermatol. 2017 Jan;176(1):255-258. doi: 10.1111/bjd.14809. Epub 2016 Dec 22. No abstract available.

PMID:
27291777
18.

Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide.

Tempescul A, Ianotto JC, Bagacean C, Salaun PY, Bocsan C, Zdrenghea M.

Int J Hematol. 2016 Sep;104(3):400-2. doi: 10.1007/s12185-016-2020-4. Epub 2016 May 27.

PMID:
27233512
19.

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.

Bagacean C, Zdrenghea M, Tempescul A, Cristea V, Renaudineau Y.

Immunotherapy. 2016 May;8(5):569-81. doi: 10.2217/imt-2015-0015. Review.

PMID:
27140410
20.

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R.

Neuro Oncol. 2016 Sep;18(9):1297-303. doi: 10.1093/neuonc/now033. Epub 2016 Mar 6.

21.

ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases.

Ungur R, Tempescul A, Berthou C, Bagacean C, Radeanu D, Muresan A, Zdrenghea M.

Onco Targets Ther. 2015 Oct 1;8:2771-3. doi: 10.2147/OTT.S89358. eCollection 2015.

22.

Exudative pericarditis in the evolution of a diffuse large B-cell lymphoma.

Bagacean C, Tempescul A, Ianotto JC, Marion V, Pop D, Zdrenghea M.

Cardiovasc J Afr. 2015 Jul 23;26(4):e9-11. doi: 10.5830/CVJA-2015-024.

23.

Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study.

Hermet E, Cabrespine A, Guièze R, Garnier A, Tempescul A, Lenain P, Bouabdallah R, Vilque JP, Frayfer J, Bordessoule D, Sibon D, Janvier M, Caillot D, Biron P, Legros L, Choufi B, Drenou B, Gorin NC, Bilger K, Tamburini J, Soussain C, Brechignac S, Bay JO; Société Française de Greffe de Moelle et de Thérapie Cellulaire.

J Geriatr Oncol. 2015 Sep;6(5):346-52. doi: 10.1016/j.jgo.2015.04.005. Epub 2015 Jun 23.

PMID:
26116168
24.

Ofatumumab in a chronic lymphocytic leukemia patient with graft versus host disease and relapse after mini-allo BMT.

Urian L, Renaudineau Y, Berthou C, Zdrenghea M, Petrov L, Tempescul A.

J BUON. 2015 Mar-Apr;20(2):668-9. No abstract available.

PMID:
26011372
25.

Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion.

Tempescul A, Bagacean C, Riou C, Bendaoud B, Hillion S, Debant M, Buors C, Berthou C, Renaudineau Y.

Eur J Haematol. 2016 Mar;96(3):229-35. doi: 10.1111/ejh.12573. Epub 2015 May 20.

PMID:
25911969
26.

Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program.

Dupuis J, Brice P, François S, Ysebaert L, de Guibert S, Levy V, Leprêtre S, Choquet S, Dilhuydy MS, Fornecker L, Morel V, Tempescul A.

Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):e43-6. doi: 10.1016/j.clml.2014.07.013. Epub 2014 Aug 1.

PMID:
25193089
27.

The arachidonic acid-LTB4-BLT2 pathway enhances human B-CLL aggressiveness.

Guriec N, Le Jossic-Corcos C, Simon B, Ianotto JC, Tempescul A, Dréano Y, Salaün JP, Berthou C, Corcos L.

Biochim Biophys Acta. 2014 Nov;1842(11):2096-105. doi: 10.1016/j.bbadis.2014.07.016. Epub 2014 Jul 26.

28.

Dissociated evolution of a multifocal primary CNS lymphoma.

Bagacean C, Zdrenghea M, Popescu C, Quintin-Roue I, Ianotto JC, Eveillard JR, Berthou C, Tempescul A.

J BUON. 2013 Oct-Dec;18(4):1098. No abstract available.

PMID:
24344046
29.

Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.

Ianotto JC, Ngo Sack F, Couturier MA, Tempescul A, Mugnier N, Delepine P, Guillerm G, Berthou C.

Leuk Lymphoma. 2014 Jan;55(1):74-7. doi: 10.3109/10428194.2013.791984. Epub 2013 Jun 5.

PMID:
23566160
30.

Severe CMV complication following maintenance therapy with rituximab.

Le Clech L, Ianotto JC, Quintin-Roue I, Tempescul A.

BMJ Case Rep. 2013 Jan 9;2013. pii: bcr2012006672. doi: 10.1136/bcr-2012-006672.

31.

Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.

Ianotto JC, Tempescul A, Amet Y, Grall P, Dalbies F, Eveillard JR, Guillerm G, Berthou C.

Am J Hematol. 2012 Apr;87(4):437-9. doi: 10.1002/ajh.23113. Epub 2012 Jan 28. No abstract available.

32.

[Acute chest syndrome of adults suffering from sickle cell disease].

Quéré G, Tempescul A, Couturaud F, Paleiron N, Leroyer C, De Saint-Martin L.

Rev Pneumol Clin. 2011 Dec;67(6):335-41. doi: 10.1016/j.pneumo.2011.07.001. Epub 2011 Oct 13. Review. French.

PMID:
22137276
33.

Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy.

Cornec D, Tempescul A, Querellou S, Hutin P, Pers JO, Jamin C, Bendaoud B, Berthou C, Renaudineau Y, Youinou P.

Ann Hematol. 2012 May;91(5):715-721. doi: 10.1007/s00277-011-1369-y. Epub 2011 Nov 16.

PMID:
22083514
34.

Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells.

Hammadi M, Youinou P, Tempescul A, Tobón G, Berthou C, Bordron A, Pers JO.

Haematologica. 2012 Feb;97(2):288-96. doi: 10.3324/haematol.2011.051938. Epub 2011 Nov 4.

35.

Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients.

Ianotto JC, Tempescul A, Yan X, Delepine P, Le Calloch R, Hardy E, Eveillard JR, Mugnier N, Berthou C, Guillerm G.

Bone Marrow Transplant. 2012 Jun;47(6):874-6. doi: 10.1038/bmt.2011.189. Epub 2011 Sep 26. No abstract available.

PMID:
21946380
36.

Delayed G-CSF stimulation after PBSCT does not seem to modify the biological parameters of bone marrow recovery.

Ianotto JC, Tempescul A, Delepine P, Guillerm G, Hardy E, Eveillard JR, Berthou C.

Am J Hematol. 2011 Apr;86(4):351-2. doi: 10.1002/ajh.21991.

37.

Relapsing acute myeloid leukemia beginning with a penile localization.

Martin-Babau J, Tempescul A, Moreau L, Staroz F, Danhier S, Guillerm G, Berthou C, Ianotto JC.

Am J Hematol. 2011 Feb;86(2):193-4. doi: 10.1002/ajh.21843. No abstract available.

38.

Hemorrhagic Cystitis due to BK Reactivation in a Young Female Treated for Hodgkin-Disease.

Le Calloch R, Ianotto JC, Berthou C, Tempescul A.

Case Rep Hematol. 2011;2011:592470. doi: 10.1155/2011/592470. Epub 2011 Jul 9.

39.

Infection by H1N1 flu virus revealing T-cell acute lymphoid leukaemia: about two cases.

Lefevre G, Ianotto JC, Tempescul A, Lemoine P, Guillerm G, Berthou C.

Ann Hematol. 2011 Sep;90(9):1111-2. doi: 10.1007/s00277-010-1132-9. Epub 2010 Dec 30. No abstract available.

PMID:
21191793
40.

Combined therapy associating systemic platinum-based chemotherapy and local radiotherapy into the treatment of primary intraocular lymphoma.

Tempescul A, Pradier O, Marianowski-Cochard C, Ianotto JC, Berthou C.

Ann Hematol. 2011 Sep;90(9):1117-8. doi: 10.1007/s00277-010-1139-2. Epub 2010 Dec 24. No abstract available.

PMID:
21184080
41.

ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.

Tempescul A, Ianotto JC, Eveillard JR, Guillerm G, Berthou C.

Ann Hematol. 2011 Aug;90(8):971-3. doi: 10.1007/s00277-010-1107-x. Epub 2010 Nov 6. No abstract available.

PMID:
21057951
42.

Acute dyspnoea and single tracheal localisation of mantle cell lymphoma.

Ianotto JC, Tempescul A, Eveillard JR, André N, Morel F, Quintin-Roué I, Berthou C.

J Hematol Oncol. 2010 Sep 28;3:34. doi: 10.1186/1756-8722-3-34.

43.

Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.

Ianotto JC, Tempescul A, Eveillard JR, Charles F, Berthou C.

Acta Haematol. 2010;123(3):146-7. doi: 10.1159/000281063. Epub 2010 Feb 5. No abstract available.

PMID:
20134156
44.

18F-FDG PET/CT in primary non-Hodgkin's lymphoma of the sinonasal tract.

Tempescul A, Querellou S, Ianotto JC, Boisramé S, Valette G, Berthou C.

Ann Hematol. 2010 Jun;89(6):635-7. doi: 10.1007/s00277-009-0842-3. Epub 2009 Oct 21. No abstract available.

PMID:
19844711
45.

Peripheral blood stem cell collection in elderly patients.

Tempescul A, Ianotto JC, Hardy E, Quivoron F, Petrov L, Berthou C.

Ann Hematol. 2010 Mar;89(3):317-21. doi: 10.1007/s00277-009-0812-9. Epub 2009 Aug 20.

PMID:
19693499
46.

A possible relationship of lupus anti-coagulant with disease activity in Hodgkin lymphoma.

Ianotto JC, Tempescul A, Eveillard JR, Malou M, Berthou C.

Leuk Lymphoma. 2009 Jan;50(1):122-3. doi: 10.1080/10428190802517757. No abstract available.

PMID:
19152175
47.

Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma.

Tempescul A, Ianotto JC, Morel F, Marion V, De Braekeleer M, Berthou C.

Ann Hematol. 2009 Sep;88(9):921-2. doi: 10.1007/s00277-008-0692-4. Epub 2009 Jan 13. No abstract available.

PMID:
19139889
48.

Tri-lineage disease involving sideroblastic anaemia, multiple myeloma and B-cell non-Hodgkin's lymphoma in the same patient.

Ianotto JC, Tempescul A, Eveillard JR, Marion V, Quintin-Roué I, Berthou C.

Ann Hematol. 2009 Mar;88(3):273-4. doi: 10.1007/s00277-008-0586-5. Epub 2008 Aug 22. No abstract available.

PMID:
18719917
49.

A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.

Tempescul A, Feuerbach J, Ianotto JC, Dalbies F, Marion V, Le Bris MJ, De Braekeleer M, Berthou C.

Ann Hematol. 2009 Jan;88(1):85-8. doi: 10.1007/s00277-008-0541-5. Epub 2008 Jul 25. No abstract available.

PMID:
18654781
50.

High-dose melphalan followed by a second bone marrow transplantation in early relapse of acute myeloid leukemia after bone marrow transplantation in children.

Tempescul A, Ianotto JC, Eveillard JR, Guillerm G, Berthou C, Marion V, De Braekeleer M.

Ann Hematol. 2008 Jun;87(6):503-4. doi: 10.1007/s00277-007-0432-1. Epub 2008 Jan 3. No abstract available.

PMID:
18172644

Supplemental Content

Loading ...
Support Center